MAGE-A and NY-ESO-1 expression in cervical cancer: Prognostic factors and effects of chemotherapy

Chiara Napoletano, Filippo Bellati, Elisabetta Tarquini, Federica Tomao, Federica Taurino, Giulio Spagnoli, Aurelia Rughetti, Ludovico Muzii, Marianna Nuti, Pierluigi Benedetti Panici

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: The aim of this study was to evaluate the prevalence of cancer testis tumor-associated antigens MAGE-A and NY-ESO-1 in cervical cancer and correlate expression patterns with clinicopathologic parameters and prognosis. Study Design: One hundred sixty-two cervical cancer samples from 109 patients who were treated with radical hysterectomy, neoadjuvant chemotherapy, or pelvic disease recurrence were analyzed by immunohistochemistry. Results: MAGE-A was expressed by 32/94 (34%) and 7/15 (47%) previously untreated and recurrent tumors, respectively. NY-ESO-1 was expressed by 46/94 (49%) and 6/15 (40%) previously untreated and recurrent tumors, respectively. MAGE-A in early stage tumors was correlated to tumor size and lymph node metastases (P = .024 and P = .046, respectively) whereas NY-ESO-1 to tumor grading (P = .039). Conclusion: Cervical cancer frequently expresses cancer testis tumor-associated antigens. MAGE-A and NY-ESO-1 expression rates are not influenced by systemic therapies. Cancer testis tumor-associated antigens are correlated to common prognostic factors.

Original languageEnglish
JournalAmerican Journal of Obstetrics and Gynecology
Volume198
Issue number1
DOIs
Publication statusPublished - Jan 2008

Keywords

  • cancer testis tumor-associated antigens
  • cervical cancer
  • MAGE-A
  • neoadjuvant chemotherapy
  • NY-ESO-1

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynaecology

Fingerprint

Dive into the research topics of 'MAGE-A and NY-ESO-1 expression in cervical cancer: Prognostic factors and effects of chemotherapy'. Together they form a unique fingerprint.

Cite this